MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.37754

Медицинская библиотека · Arthritis and rheumatism · 2013

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

Oddis Chester V, Reed Ann M, Aggarwal Rohit, Rider Lisa G, Ascherman Dana P, Levesque Marc C, Barohn Richard J, Feldman Brian M, Harris-Love Michael O, Koontz Diane C, Fertig Noreen, Kelley Stephanie S, Pryber Sherrie L, Miller Frederick W, Rockette Howard E, RIM Study Group

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПеревод в очереди

Аннотация

OBJECTIVE

To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial in adult and pediatric myositis patients.

METHODS

Adults with refractory polymyositis (PM) and adults and children with refractory dermatomyositis (DM) were enrolled. Entry criteria included muscle weakness and ≥2 additional abnormal values on core set measures (CSMs) for adults. Juvenile DM patients required ≥3 abnormal CSMs, with or without muscle weakness. Patients were randomized to receive either rituximab early or rituximab late, and glucocorticoid or immunosuppressive therapy was allowed at study entry. The primary end point compared the time to achieve the International Myositis Assessment and Clinical Studies Group preliminary definition of improvement (DOI) between the 2 groups. The secondary end points were the time to achieve ≥20% improvement in muscle strength and the proportions of patients in the early and late rituximab groups achieving the DOI at week 8.

RESULTS

Among 200 randomized patients (76 with PM, 76 with DM, and 48 with juvenile DM), 195 showed no difference in the time to achieving the DOI between the rituximab late (n = 102) and rituximab early (n = 93) groups (P = 0.74 by log rank test), with a median time to achieving a DOI of 20.2 weeks and 20.0 weeks, respectively. The secondary end points also did not significantly differ between the 2 treatment groups. However, 161 (83%) of the randomized patients met the DOI, and individual CSMs improved in both groups throughout the 44-week trial.

CONCLUSION

Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI. The role of B cell-depleting therapies in myositis warrants further study, with consideration for a different trial design.

Для цитирования: Oddis Chester V, Reed Ann M, Aggarwal Rohit, Rider Lisa G, Ascherman Dana P, Levesque Marc C, Barohn Richard J, Feldman Brian M, Harris-Love Michael O, Koontz Diane C, Fertig Noreen, Kelley Stephanie S, Pryber Sherrie L, Miller Frederick W, Rockette Howard E, RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.. Arthritis and rheumatism. 2013. DOI: 10.1002/art.37754.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.